A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Prior treatment

• History or planned organ or allogeneic stem cell transplantation.
• Active or prior documented autoimmune or inflammatory disorders, within the past 3 years
• Any prior toxicities that led to permanent discontinuation of prior immunotherapy
• Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy
• Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids
• Prior history of Grade ≥ 3 non-infectious pneumonitis.
• Participant requires chronic immunosuppressive therapy (including steroids \> 10 mg prednisone/day or equivalent).
• Receipt of live attenuated vaccine within 30 days.
  • Module 2 specific exclusion criteria:
• Previous treatment with anti-TIGIT therapy

Other illness

• Any evidence of:
  • Severe or uncontrolled systemic diseases including respiratory, cardiac or tumor-related conditions
• Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis.
• Active uncontrolled or chronic infection of hepatitis B, hepatitis C

Lab values

• 1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC

• Participant ≥ 18 year
• ECOG PS of 0 to 1
• Provision of 'archival' tumor specimen
• At least one measurable lesion according to RECIST v1.1,
• Minimum life expectancy of 12 weeks
• Adequate and stable cardiac function
• Adequate bone marrow, liver and kidney function
• Body weight ≥ 35 kg
• Capable of giving signed informed consent
  • Module 1 specific inclusion criteria:
• Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinoma of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancer/gastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC
  • Module 2 specific inclusion criteria:
• Participants with Stage IV NSCLC Dose Escalation/Backfills
  • Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR
  • Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.
  • Dose Expansion
  • <!-- -->
  • Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.